Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients.

Pharmacogenomics - 1 Feb 2018

Rafeeq Misbahuddin Mohd, Habib Hamed Said, Murad Hussam Aly Sayed, Gari Mamdouh Abdullah, Gazzaz Zohair Jamil

Abstract excerpt

AIM: Genetic variants contribute to statins' therapeutic variability. SREBF-SCAP pathway is a key player in lipid homeostasis. Hence, effect of SREBF-SCAP polymorphisms on therapeutic response was studied. PATIENTS & METHODS: Metabolic syndrome patients of either sex were prescribed rosuvastatin 10 mg for 24 weeks. Clinical, anthropometric and lipid measurements were done before and after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors
Share to Intracellular Signaling Peptides and Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipids

Share to Membrane Proteins

Share to Metabolic Syndrome

Share to Rosuvastatin Calcium

Share to Signal Transduction

Share to Sterol Regulatory Element Binding Protein 1

Source

Identifiers

PMID: 29318930
DOI: 10.2217/pgs-2017-0181

Genes

SCAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients.PMID 29318930Read ↗

Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.Semantic proximity Read ↗

Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes.Semantic proximity Read ↗

Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin.Semantic proximity Read ↗

Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug.Semantic proximity Read ↗

SCAP gene polymorphisms decrease the risk of nonalcoholic fatty liver disease in females with metabolic syndrome.Semantic proximity Read ↗

Correlation between SCAP Genetic Polymorphism and Coronary Artery Disease in a Han population in Xinjiang, ChinaSemantic proximity Read ↗

Statins personalized.Semantic proximity Read ↗

The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients.Semantic proximity Read ↗

Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.Semantic proximity Read ↗

Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population.Semantic proximity Read ↗

The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.Semantic proximity Read ↗

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.